New appropriate use criteria for lumbar puncture in Alzheimer's diagnosis

October 10, 2018, Alzheimer's Association

In preparation for more tools that detect and measure the biology associated with Alzheimer's and other dementias earlier and with more accuracy, an Alzheimer's Association-led Workgroup has published appropriate use criteria (AUC) for lumbar puncture (spinal tap) and spinal fluid analysis in the diagnosis of Alzheimer's disease.

The AUC is available online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association as an article in press, corrected proof.

"Early and accurate diagnosis of Alzheimer's is critical as therapies that have the potential to stop or slow the progression of the disease become available," said Maria C. Carrillo, Ph.D., Chief Science Officer at the Alzheimer's Association. "These criteria will arm medical professionals with necessary guidance when the use of is an appropriate part of the process to diagnose Alzheimer's disease and other dementias, thereby giving people with and their families the possibility of a head start in preparing for the course of their disease."

Alzheimer's disease is commonly diagnosed by a thorough examination of physical health, medical history and assessment of memory, thinking and reasoning. Lumbar puncture, while not currently in routine clinical practice in the U.S., is anticipated to be a safe and cost-effective way to retrieve cerebrospinal fluid (CSF) to test for biological markers of Alzheimer's disease, potentially delivering valuable diagnostic information to clinicians and their earlier in the course of the disease.

The Workgroup's efforts complement the 2013 AUC for brain amyloid PET scans developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer's Association.

The lumbar puncture AUC criteria recommend clinicians consider the following patient populations as appropriate and inappropriate:

Appropriate uses of lumbar puncture:

  • A patient has subjective cognitive decline (SCD) and is considered to be at an increased risk for Alzheimer's disease based on indicators that include a persistent decline in memory, younger onset age (>60), onset in the last 5 years and others. The decision to perform CSF biomarker testing in this case should be individualized and most strongly supported when the individual, family and clinician all are concerned about the patient's cognitive decline.
  • A patient has (MCI) that is persistent, progressive and unexplained. MCI includes mild deficits on cognitive testing but no change in functional abilities.
  • A patient has symptoms that suggest possible Alzheimer's disease, meaning the dementia could be due to another cause.
  • A patient has MCI or dementia with onset at an early age (<65).
  • A patient meets core clinical criteria for probable Alzheimer's disease with typical age of onset.
  • A patient's dominant symptom is an unexplained change in behavior, such as delusions and delirium, and an Alzheimer's disease diagnosis is being considered.

Inappropriate uses of lumbar puncture:

  • A patient is cognitively unimpaired, is within the normal range of functioning for their age and lacks significant risk factors for Alzheimer's disease.
  • A patient is cognitively unimpaired but is considered to be at risk for Alzheimer's disease based on their family history.
  • A patient has SCD and has been evaluated and found by a clinician not to be at high risk for Alzheimer's disease based on indications such as no family history or limited concern from an informant like a partner or family member.
  • A patient has symptoms of rapid eye movement (REM) sleep behavior disorder, which is a strong predictor of disorders such as Parkinson's disease and Lewy body dementia.
  • A patient already has been diagnosed with Alzheimer's and the test's use would be to determine the stage of their disease or its severity.
  • A patient is an apolipoprotein E-e4 (ApoE-e4) carrier who has no cognitive impairment. ApoE-e4 is a genetic mutation strongly associated with risk for late-onset Alzheimer's.
  • The test is being used in lieu of genotyping for individuals who are suspected to carry a rare genetic mutation that causes an early-onset form of Alzheimer's disease.

The AUC includes suggestions from the workgroup on implementing the criteria in clinical practice. They recommend that CSF biomarker testing be done by dementia experts who can determine the appropriateness of the test, educate the patient and family about the benefits and risks, ensure the procedure follows established guidelines, and integrate the results into the patient's treatment plan.

Explore further: Exercise may delay cognitive decline in people with rare Alzheimer's disease

More information: "Appropriate Use Criteria for Lumbar Puncture and Cerebrospinal Fluid Testing in the Diagnosis of Alzheimer's Disease," by Leslie M. Shaw, Ph.D, et al, is available online Oct. 10, 2018, as an article in press corrected proof at www.alzheimersanddementia.com .

Related Stories

Exercise may delay cognitive decline in people with rare Alzheimer's disease

September 25, 2018
For individuals carrying a genetic mutation that causes Alzheimer's disease, engaging in at least 2.5 hours of physical activity per week may have beneficial effects on markers of Alzheimer's disease brain changes and may ...

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

New biomarker may help with early diagnosis of Alzheimer's disease

June 22, 2011
A new biomarker may help identify which people with mild memory deficits will go on to develop Alzheimer's disease, according to a new study published in the June 22, 2011, online issue of Neurology, the medical journal of ...

New way of defining Alzheimer's aims to find disease sooner

April 10, 2018
Government and other scientists are proposing a new way to define Alzheimer's disease—basing it on biological signs, such as brain changes, rather than memory loss and other symptoms of dementia that are used today.

Brain amyloid PET scans enhance the diagnosis of Alzheimer's

July 17, 2017
The build-up of amyloid protein in the brain is a hallmark feature of Alzheimer's disease, and its detection often relies on the testing of brain and spinal fluid samples. More recently, PET brain scans have been able to ...

Recommended for you

Hypothesis underpinning dementia research 'flawed'

October 16, 2018
A hypothesis which has been the standard way of explaining how the body develops Alzheimer's Disease for almost 30 years is flawed, according to a University of Manchester biologist.

Study suggests biological basis for depression, anxiety, sleep disturbances in older adults

October 15, 2018
UC San Francisco researchers, in collaboration with the unique Brazilian Biobank for Aging Studies (BBAS) at the University of São Paulo, have shown that the earliest stages of the brain degeneration associated with Alzheimer's ...

Many cases of dementia may arise from non-inherited DNA 'spelling mistakes'

October 15, 2018
Only a small proportion of cases of dementia are thought to be inherited—the cause of the vast majority is unknown. Now, in a study published today in the journal Nature Communications, a team of scientists led by researchers ...

Scientists create new map of brain region linked to Alzheimer's disease

October 8, 2018
Curing some of the most vexing diseases first requires navigating the world's most complex structure—the human brain. So, USC scientists have created the most detailed atlas yet of the brain's memory bank.

Previously unknown genetic aberrations found to be associated with Alzheimer's progression

October 8, 2018
In a large-scale analysis of RNA from postmortem human brain tissue, researchers at the Icahn School of Medicine at Mount Sinai and Columbia University have identified specific RNA splicing events associated with Alzheimer's ...

Periodontal disease bacteria may kick-start Alzheimer's

October 4, 2018
Long-term exposure to periodontal disease bacteria causes inflammation and degeneration of brain neurons in mice that is similar to the effects of Alzheimer's disease in humans, according to a new study from researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.